In our work, we supplied direct evidence demonstrating that knockdown of KIF11 significantly improved the chemotherapy sensitivity of CRC to oxaliplatin, a commonly used chemotherapeutic drug, via enhanced DNA damage and apoptosis. The gene discussed is KIF11; the disease is colorectal carcinoma.